{
    "clinical_study": {
        "@rank": "18254", 
        "arm_group": [
            {
                "arm_group_label": "Myo-inositol normospermic", 
                "arm_group_type": "Sham Comparator", 
                "description": "29 normospermic treated with 4000mg/die of myo-inositol and 400 \u00b5g of folic acid"
            }, 
            {
                "arm_group_label": "Myo-inositol OAT", 
                "arm_group_type": "Active Comparator", 
                "description": "13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 \u00b5g of folic acid"
            }, 
            {
                "arm_group_label": "Folic acid normospermic", 
                "arm_group_type": "Placebo Comparator", 
                "description": "20 normospermic patients treated with 400 \u00b5g of folic acid"
            }
        ], 
        "brief_summary": {
            "textblock": "Many clinical evidences suggest that Myo-inositol plays a crucial role in human\n      reproduction. Also, it was shown that Myo-inositol concentration in the seminiferous tubules\n      was higher than in serum, and interestingly it was increasing through the epididymis and the\n      deferent duct mining that sperm cell before ejaculation are stored in a \"medium\" highly\n      enriched in myo-inositol.\n\n      Starting from this evidences, the investigators hypothesized that myo-inositol may be a\n      possible factor able to improve the semen parameters of samples used in in vitro\n      fertilization cycles."
        }, 
        "brief_title": "Myo-inositol on Human Semen Parameters", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Asthenozoospermia", 
            "Oligospermia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Oligospermia", 
                "Asthenozoospermia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Samples of seminal fluid were obtained from two groups of patients undergoing to an IVF\n      cycle: healthy normospermic subjects and subjects with oligoasthenoteratospermia (OAT, < 15\n      mil/ml).\n\n      Semen volume, spermatozoa number and motility were evaluated during the initial semen\n      analysis and after density gradient separation method. These parameters were evaluated\n      before and after the administration of 4000mg/die of myo-inositol associated to 400 \u00b5g of\n      folic acid (Inofolic lolipharma Rome) for three months.\n\n      A third group of healthy normospermic subject were traded with 400 \u00b5g of folic acid for\n      three months and was consider a control group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Undergoing to IVF cycle OAT\n\n        Exclusion Criteria:\n\n        No undergoing to IVF cycle"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828710", 
            "org_study_id": "INO-2103-GC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Myo-inositol normospermic", 
                "description": "4000mg/die of myo-inositol and 400 \u00b5g of folic acid (Inofolic\u00ae Lo.Li. pharma s.r.l., Roma) for three months.", 
                "intervention_name": "Myo-inositol normospermic", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Myo-inositol OAT", 
                "description": "B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 \u00b5g of folic acid (Inofolic\u00ae Lo.Li. pharma s.r.l., Roma) for three months", 
                "intervention_name": "Myo-inositol OAT", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Folic acid normospermic", 
                "description": "Group C 20 normospermic patients treated with 400 \u00b5g of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.", 
                "intervention_name": "Folic Acid normospermic", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vitamin B Complex", 
                "Inositol", 
                "Hematinics"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Myo-inositol", 
            "oligoasthenoteratospermia", 
            "semen parameters", 
            "IVF"
        ], 
        "lastchanged_date": "April 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Catania", 
                    "country": "Italy", 
                    "state": "CT", 
                    "zip": "95010"
                }, 
                "name": "Centre of Physiopathology of Reproduction"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing IVF Cycles", 
        "overall_official": [
            {
                "affiliation": "University of Catania - Department of Surgery - Section of Obstetrics and Gynecology -  Centre of Physiopathology of Reproduction", 
                "last_name": "Marco Palumbo, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "A.G.Un.Co. Obstetrics and gynaecology center", 
                "last_name": "Gianfranco Carlomagno, Ph.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: National Institute of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "sperm concentration", 
            "safety_issue": "No", 
            "time_frame": "after 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828710"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AGUNCO Obstetrics and Gynecology Centre", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AGUNCO Obstetrics and Gynecology Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}